Altimmune (NASDAQ:ALT) Receives “Overweight” Rating from Piper Sandler

Piper Sandler reissued their overweight rating on shares of Altimmune (NASDAQ:ALT) in a report released on Friday morning, Benzinga reports. The brokerage currently has a $25.00 price objective on the stock.

A number of other research analysts have also weighed in on ALT. JMP Securities reduced their target price on Altimmune from $25.00 to $24.00 and set a market outperform rating for the company in a report on Friday, May 10th. Guggenheim lowered shares of Altimmune from a buy rating to a neutral rating in a report on Monday, April 29th. B. Riley reiterated a buy rating and issued a $20.00 target price on shares of Altimmune in a research note on Thursday, March 28th. Finally, HC Wainwright restated a buy rating and set a $12.00 price target on shares of Altimmune in a research report on Tuesday, May 14th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Altimmune currently has a consensus rating of Moderate Buy and a consensus target price of $18.80.

Altimmune Stock Up 7.9 %

NASDAQ ALT opened at $6.41 on Friday. The firm has a market cap of $454.47 million, a P/E ratio of -4.03 and a beta of 0.11. The company’s 50 day moving average is $7.15 and its 200-day moving average is $8.74. Altimmune has a 12-month low of $2.09 and a 12-month high of $14.84.

Altimmune (NASDAQ:ALT) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.02. Altimmune had a negative net margin of 22,645.37% and a negative return on equity of 46.96%. The business had revenue of $0.01 million during the quarter. During the same quarter in the prior year, the firm posted ($0.40) earnings per share. Equities analysts expect that Altimmune will post -1.34 EPS for the current year.

Hedge Funds Weigh In On Altimmune

A number of institutional investors have recently made changes to their positions in ALT. WealthPlan Investment Management LLC bought a new position in shares of Altimmune during the 3rd quarter valued at about $31,000. North Star Investment Management Corp. purchased a new position in shares of Altimmune during the first quarter worth approximately $31,000. FNY Investment Advisers LLC bought a new stake in shares of Altimmune in the 4th quarter worth approximately $35,000. CANADA LIFE ASSURANCE Co purchased a new stake in shares of Altimmune in the 1st quarter valued at $44,000. Finally, Russell Investments Group Ltd. grew its holdings in shares of Altimmune by 1,150.9% during the 4th quarter. Russell Investments Group Ltd. now owns 4,303 shares of the company’s stock valued at $48,000 after purchasing an additional 3,959 shares during the last quarter. Institutional investors own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.